The initiative supports 14 MedTech startups innovating in diagnostics, treatment, and care across key health areas
New Delhi
The Department for Promotion of Industry and Internal Trade (DPIIT) has signed a Memorandum of Understanding (MoU) with US-based pharmaceutical company Pfizer to strengthen India’s healthcare sector and accelerate the lab-to-market journey of innovations. The Ministry of Commerce and Industry confirmed the partnership on Thursday.
The collaboration will provide both financial and non-financial support to DPIIT-recognised startups. Through the Pfizer INDovation programme, selected startups will receive grants of up to ₹60 lakh each, alongside an 18-month customised incubation programme run by Social Alpha. This support includes expert mentorship, infrastructure, global networking opportunities, and exposure at Pfizer’s Research and Development centre in Chennai.
The initiative will focus on 14 MedTech startups working on innovations in screening, diagnostics, health monitoring, and treatment solutions. Key areas of emphasis include non-communicable diseases, oncology, brain health, maternal and child care, and immunisation. Startups will also benefit from guidance in clinical validation, regulatory processes, and go-to-market strategies.
“India needs to move towards novel drug discovery, and startups will play a key role in this journey,” said Sanjiv, Joint Secretary, DPIIT. Sharad Goswami, Senior Director – Global Policy and Public Affairs, Pfizer India, reiterated the company’s commitment to supporting patient-centric healthcare solutions tailored to India’s needs.
The MoU reflects DPIIT’s broader push for impactful public-private partnerships aimed at inclusive growth and innovation. Just last month, DPIIT signed a similar agreement with Roche to assist startups in areas like oncology, neurology, ophthalmology, haematology, and rare diseases. That collaboration promised mentorship, pilot studies, advanced infrastructure, and access to international platforms.
